Dexibuprofen Therapeutic Advances: Prodrugs and Nanotechnological Formulations
Anna Gliszczyńska , Elena Sánchez-López
AbstractS-(+) enantiomer of ibuprofen (IBU) dexibuprofen (DXI) is known to be more potent than its R-(−) form and exhibits many advantages over the racemic mixture of IBU such as lower toxicity, greater clinical efficacy, and lesser variability in therapeutic effects. Moreover, DXI potential has been recently advocated to reduce cancer development and prevent the development of neurodegenerative diseases in addition to its anti-inflammatory properties. During the last decade, many attempts have been made to design novel formulations of DXI aimed at increasing its therapeutic benefits and minimizing the adverse effects. Therefore, this article summarizes pharmacological information about DXI, its pharmacokinetics, safety, and therapeutic outcomes. Moreover, modified DXI drug delivery approaches are extensively discussed. Recent studies of DXI prodrugs and novel DXI nanoformulations are analyzed as well as reviewing their efficacy for ocular, skin, and oral applications.
|Journal series||Pharmaceutics, ISSN 1999-4923, (N/A 100 pkt)|
|Publication size in sheets||0.85|
|Keywords in English||dexibuprofen; NSAIDs; enantiomer; drug delivery; prodrugs|
|License||Journal (articles only); published final; ; with publication|
|Score||= 100.0, 29-03-2021, ArticleFromJournal|
|Publication indicators||: 2016 = 1.097; : 2018 = 4.773 (2)|
* presented citation count is obtained through Internet information analysis and it is close to the number calculated by the Publish or Perish system.